The 2026 Orphan Drug Reset: What Catalyst Fix Changes for Repurposing

In February 2026, Congress quietly reversed a five-year-old court ruling that had crashed U.S. orphan drug approvals by more than half. For drug repurposing companies, the territory that was locked shut has just reopened.

The 56% Collapse

Between late 2021 and early 2023, something went wrong with the FDA's orphan drug pipeline. The agency approved 217 orphan drug applications in the 16 months before September 2021. In the 16 months after, that number fell to 95.

This was not a research failure. The underlying science had not changed. Clinical pipelines had not collapsed. What changed was a single court ruling — and how it expanded the scope of existing orphan drug monopolies until new entrants had nowhere to go.

The ruling was Catalyst Pharmaceuticals v. Becerra, decided by the Eleventh Circuit Court of Appeals in September 2021. In February 2026, Congress reversed it. The story of what broke, and what was fixed, is the single most important piece of 2026 regulatory news for any company working on rare disease drug repurposing.

How Catalyst Broke the System

The Orphan Drug Act of 1983 grants seven years of market exclusivity to the first drug approved for a rare disease. The question has always been: exclusivity for what exactly?

For forty years, the FDA answered with a specific interpretation. Exclusivity applied to the approved use or indication, not to the entire disease. If Drug A was approved to treat Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, Drug B could still seek approval for LEMS in children, or for a different clinical presentation of the same condition, or for the same patients with a meaningfully different mechanism of action.

The Eleventh Circuit rejected this interpretation in Catalyst. The court read the statutory phrase "same disease or condition" at face value. If the orphan designation named the disease, then the exclusivity covered the disease — all of it. Every patient subpopulation. Every unapproved indication within the condition. Every other molecule that competitors might develop for the same rare disease.

The FDA initially tried to contain the ruling by applying it only to Catalyst itself. That containment collapsed in Neurelis v. Brenner, where a district court extended the Catalyst logic to block approval of a rescue therapy (Libervant) for pediatric seizure patients because an adult indication was already held by a competitor (Valtoco).

The practical effect was simple. Any orphan designation granted in the 2010s now risked functioning as a disease-wide monopoly. Companies that had invested years in developing alternative therapies for rare conditions found their paths to approval blocked retroactively. And prospective developers faced a new question before committing to any rare disease program: does an existing orphan drug already cover this entire disease, regardless of its actual approved label?

In many cases, the answer was unclear. So capital retreated. Approvals collapsed.

The Fix: Section 6605

On February 3, 2026, President Trump signed the Consolidated Appropriations Act of 2026. Buried within it was Section 6605 of the Mikaela Naylon Give Kids a Chance Act — a narrowly targeted legislative fix that unwound the Catalyst ruling in a single paragraph.

The amendment changed the operative statutory language in exactly one way:

"same disease or condition" → "same approved use or indication within such rare disease or condition"

The change was retroactive. It applies to every orphan drug currently holding exclusivity, regardless of when that drug was designated or approved. The FDA is now required to audit its active exclusivity database and recalibrate the scope of protection for every product on the list.

Three consequences follow immediately.

Why This Matters for Drug Repurposing

Drug repurposing — identifying new therapeutic applications for existing approved drugs — sits at the intersection of exclusivity law in a way that few other strategies do.

A repurposing candidate typically targets a specific indication within a rare disease. It may be a different clinical manifestation, a different patient subgroup, a different disease stage, or a new mechanism for treating the same underlying pathology. Under the Catalyst framework, if an orphan drug already held disease-wide exclusivity, the repurposing path was blocked before it began. Under Section 6605, only the specific approved indication is blocked. Everything else is open.

Consider a concrete scenario. Suppose Drug X is approved for the treatment of cardiac manifestations of a rare genetic disease. Under the Catalyst interpretation, no other company could develop any drug — including a different molecule — for any aspect of that disease during the exclusivity period. Under Section 6605, a repurposing candidate targeting the neurological manifestations of the same disease is no longer automatically blocked.

This is the territory that just reopened. And because the change is retroactive, the reopening applies to diseases where exclusivity was granted years ago.

What the FDA Audit Means in Practice

The retroactive audit is not just a paperwork exercise. It requires the FDA to re-examine hundreds of active orphan exclusivities and formally narrow the scope of each to the specific approved indication.

For companies evaluating repurposing opportunities, this creates a specific window of strategic value. A drug-disease combination that appeared blocked six months ago may now be viable. A program that was shelved in 2022 may deserve re-evaluation. A competitive intelligence map built on pre-2026 assumptions about orphan exclusivity scope is almost certainly wrong.

The open question for every rare disease drug repurposing company right now is the same: which of our shelved candidates just came back to life?

Answering that question at scale requires methodical evaluation. Each candidate drug-disease combination needs to be assessed against the newly narrowed scope of relevant orphan exclusivities, the specific approved indication of any incumbent drug, and the regulatory pathway most likely to succeed (505(b)(2) applications remain the typical vehicle for repurposed small molecules).

The New Rules of Engagement

Three things change for anyone building a rare disease drug repurposing program in 2026.

First, previously blocked combinations are worth a second look. If a repurposing candidate was dismissed because an existing orphan drug held disease-wide exclusivity, that reasoning no longer applies. The specific approved indication of the incumbent is now the only barrier, and many incumbents are approved for narrow indications relative to the full clinical scope of the disease they address.

Second, pediatric subpopulations just became strategically important again. The Catalyst ruling had a particularly chilling effect on pediatric development, because adult approvals frequently blocked pediatric programs for the same disease. Section 6605 explicitly reopens this space. Combined with the reauthorization of the Rare Pediatric Disease Priority Review Voucher program through 2029 (also part of the Give Kids a Chance Act), pediatric rare disease repurposing now sits in the most favorable regulatory environment in years.

Third, the FDA's retroactive audit creates timing pressure. Companies with candidates waiting in the wings have an incentive to engage with the agency early, while the audit is still in progress, rather than after competitors have moved into newly opened territory.

What to Do Next

For most rare disease drug repurposing companies, the appropriate next step is a methodical review of the candidate portfolio against the post-2026 regulatory landscape. This is not a single question. It requires evaluating each candidate drug-disease combination across multiple dimensions: orphan drug designation status, approved indication specificity of any incumbent, 505(b)(2) eligibility, patent landscape, and available efficacy evidence.

Most of these assessments can be completed in a focused two-to-three week engagement per candidate. The output is typically a go/no-go recommendation with explicit reasoning on each dimension — a document that can anchor internal prioritization decisions or support partnership conversations.

The orphan drug landscape in 2026 is not the same landscape as 2021. Companies that recalibrate first will find themselves operating in a market with fewer competitors, clearer rules, and four years of pent-up repurposing opportunity waiting to be evaluated.